These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 30943918)

  • 1. Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
    Djuzenova CS; Fiedler V; Memmel S; Katzer A; Sisario D; Brosch PK; Göhrung A; Frister S; Zimmermann H; Flentje M; Sukhorukov VL
    BMC Cancer; 2019 Apr; 19(1):299. PubMed ID: 30943918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.
    Memmel S; Sisario D; Zöller C; Fiedler V; Katzer A; Heiden R; Becker N; Eing L; Ferreira FLR; Zimmermann H; Sauer M; Flentje M; Sukhorukov VL; Djuzenova CS
    Oncotarget; 2017 Jul; 8(28):45298-45310. PubMed ID: 28424411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
    Djuzenova CS; Fischer T; Katzer A; Sisario D; Korsa T; Steussloff G; Sukhorukov VL; Flentje M
    BMC Cancer; 2021 Nov; 21(1):1201. PubMed ID: 34763650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
    Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN mutant cell lines.
    Kalhori MR; Irani S; Soleimani M; Arefian E; Kouhkan F
    J Cell Biochem; 2019 Oct; 120(10):16760-16774. PubMed ID: 31243804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
    Yacoub A; Mitchell C; Hong Y; Gopalkrishnan RV; Su ZZ; Gupta P; Sauane M; Lebedeva IV; Curiel DT; Mahasreshti PJ; Rosenfeld MR; Broaddus WC; James CD; Grant S; Fisher PB; Dent P
    Cancer Biol Ther; 2004 Aug; 3(8):739-51. PubMed ID: 15197348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
    Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild‑type IDH1 affects cell migration by modulating the PI3K/AKT/mTOR pathway in primary glioblastoma cells.
    Shen X; Wu S; Zhang J; Li M; Xu F; Wang A; Lei Y; Zhu G
    Mol Med Rep; 2020 Sep; 22(3):1949-1957. PubMed ID: 32705169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.
    Memmel S; Sukhorukov VL; Höring M; Westerling K; Fiedler V; Katzer A; Krohne G; Flentje M; Djuzenova CS
    PLoS One; 2014; 9(1):e87052. PubMed ID: 24498019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.
    Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH
    Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carnosine inhibits glioblastoma growth independent from PI3K/Akt/mTOR signaling.
    Oppermann H; Faust H; Yamanishi U; Meixensberger J; Gaunitz F
    PLoS One; 2019; 14(6):e0218972. PubMed ID: 31247000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.